UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo (STO:ORX) announces that ProStrakan Group plc (LSE:PSK) Orexo’s partner for Abstral in Europe and North America, today confirms that it has completed the reimbursement pricing process with the French authorities for its pan-European breakthrough cancer pain product, Abstral, earlier than expected and, as a result, plans to launch this product in the important French market next month.
